四氧嘧啶型糖尿病模型小鼠糖耐量和肝糖原与大豆胰蛋白酶抑制剂的干预

背景：研究提示大豆胰蛋白酶抑制剂（soybean trypsin inhibitor,SBTI）对治疗糖尿病,调节胰岛素失调可能有一定效果。目的：观察SBTI对四氧嘧啶糖尿病模型小鼠血糖、糖耐量及肝糖原的影响。方法：采用腹腔注射四氧嘧啶方法制备小鼠糖尿病模型,将造模成功的32只小鼠随机等分为4组,另取正常8只小鼠作为对照组。造模后,SBTI-L、SBTI-H组每日分别灌胃0.27,0.80mg/kgSBTI溶液,格列本脲组每日灌胃优降糖0.16g/kg,模型组和对照组每日灌胃生理盐水,持续给药2周。给药第0,7,14天,采用葡萄糖氧化酶法测定小鼠空腹血糖和糖耐量,改良蒽酮法测定小鼠肝糖原含量。结果与结论：与模型组比较,格列本脲组、SBTI-L组、SBTI-H组血糖明显下降（P〈0.05）,糖耐量升幅明显减小（P〈0.05）,肝糖原含量明显增加（P〈0.05）,且SBTI-L组、SBTI-H组较格列本脲组起效快,作用时间长,以SBTI-H组效果最明显。表明SBTI有明显的降血糖、改善糖耐量、提高肝糖原含量的作用。

Effects of soybean trypsin inhibitor on glucose tolerance and hepatic glycogen in alloxan diabetic mice

BACKGROUND：Previous studies found soybean trypsin inhibitor（SBTI） may have effect on treating diabetes mellitus and regulating insulin disturbance.OBJECTIVE：To study the effects of SBTI on blood glucose,glucose tolerance,and hepatic glycogen in alloxan diabetic mice.METHODS：Alloxan diabetic mice models were prepared by intraperitoneal injection of alloxan,and 32 mice with successful model preparation were randomly divided into 4 groups,additional 8 mice were served as control.After model preparation,mice in the SBTI-L and SBTI-H groups were lavaged with 0.27 and 0.80 mg/kg SBTI solution,those in the glibenclamide group was lavaged with 0.16 g/kg glibenclamide.Saline was lavaged in the model and control groups.The medication lasted for 2 weeks.The blood glucose and glucose tolerance of mice were measured by using glucose oxidase method,and the content of hepatic glycogen was determined by the improved anthrone method.RESULTS AND CONCLUSION：Compared with the model group,the blood glucose of glibenclamide,SBTI-L,and SBTI-H groups was significantly decreased（P 0.05）,and the glucose tolerance rise lower（P 0.05）,but the hepatic glycogen increased obviously（P 0.05）.The SBTI-L and SBTI-H groups showed faster effect and longer effectiveness than the glibenclamide group,especially more manifest in the SBTI-H group.Experimental results show that SBTI can significantly decrease blood glucose,improve glucose tolerance,and increase the content of hepatic glycogen.